Ohio Hemp Law Enforcement: Regulations, Challenges, and Compliance Guide

Executive Summary

Ohio's 2024 hemp law remains partially unenforceable in mid-2026 due to ongoing federal court challenges and jurisdictional disputes over interstate commerce. The state enacted comprehensive hemp regulations in late 2024 to restrict intoxicating hemp-derived cannabinoids like delta-8 THC and THCA, but enforcement has been blocked against out-of-state retailers and online sellers who argue federal law preempts state restrictions. Ohio's Department of Commerce and Board of Pharmacy have successfully enforced the law against in-state brick-and-mortar retailers, resulting in over 200 compliance actions since January 2025. However, federal district courts have issued preliminary injunctions protecting interstate sellers, creating a two-tier enforcement landscape that frustrates state regulators and advantages companies operating across state lines. The legal battle centers on whether the 2018 Farm Bill's legalization of hemp commerce prevents states from restricting specific cannabinoids derived from legal hemp. With an estimated $180 million in annual Ohio hemp-derived cannabinoid sales, the enforcement gap has significant market and public health implications as the state attempts to channel intoxicating products through its licensed adult-use cannabis program that launched in August 2024.

Why This Matters

The enforcement deadlock affects millions of Ohio consumers, hundreds of businesses, and sets precedent for hemp regulation nationwide. Ohio's 11.8 million residents have access to intoxicating hemp products through multiple channels: the state's licensed adult-use cannabis dispensaries (which opened following voter approval of Issue 2 in November 2023), traditional hemp retailers, gas stations, and online vendors. The regulatory confusion creates consumer safety concerns, as products sold outside the licensed system lack testing requirements for potency, pesticides, and contaminants. For Ohio's licensed cannabis operators, the enforcement gap represents unfair competition. Licensed dispensaries pay $150,000 in initial licensing fees plus 10% cultivation and 10% retail excise taxes, while unlicensed hemp sellers face no such burdens. The Ohio Medical Marijuana Control Program reported that licensed operators lost an estimated $40 million in potential revenue during Q1 2026 to untaxed hemp product sales. Law enforcement agencies face operational challenges. The Ohio State Highway Patrol and local police departments cannot reliably distinguish legal hemp flower (under 0.3% delta-9 THC by dry weight) from illegal cannabis without laboratory testing that costs $200-400 per sample and takes 2-3 weeks. Prosecutions for cannabis possession dropped 67% between 2024 and 2025 according to the Ohio Attorney General's office, as prosecutors decline cases they cannot prove beyond reasonable doubt. Public health officials at the Ohio Department of Health have documented 312 emergency room visits in 2025 attributed to high-potency hemp-derived products, particularly among adolescents who purchased delta-8 vape cartridges marketed with candy-like flavors and packaging. Poison control centers reported a 340% increase in calls related to hemp-derived cannabinoid exposure between 2023 and 2025. The economic stakes extend beyond Ohio. The national hemp-derived cannabinoid market reached $2.8 billion in 2025, with 23 states attempting various regulatory restrictions. How federal courts resolve Ohio's enforcement authority will influence whether states can meaningfully regulate hemp-derived intoxicants or whether the 2018 Farm Bill created an unintended nationwide market for unregulated psychoactive products.

Background and History

Ohio's hemp enforcement crisis emerged from the collision of federal hemp legalization, state cannabis reform, and the rapid commercialization of intoxicating hemp-derived cannabinoids.

The 2018 Farm Bill Foundation

The Agriculture Improvement Act of 2018, signed December 20, 2018, removed hemp (defined as cannabis with no more than 0.3% delta-9 THC on a dry weight basis) from Schedule I of the Controlled Substances Act. Section 297A of the Farm Bill explicitly preserved state authority to regulate hemp production but created ambiguity about state power to restrict hemp-derived products in interstate commerce. The U.S. Department of Agriculture established the U.S. Domestic Hemp Production Program in October 2019, creating a federal regulatory framework for hemp cultivation. Ohio launched its hemp cultivation program in 2019 under the Ohio Department of Agriculture, issuing 1,200 grower licenses by 2020. Early hemp commerce focused on CBD products marketed for wellness purposes, with minimal regulatory controversy.

The Delta-8 THC Explosion (2020-2022)

In 2020, manufacturers discovered they could convert CBD extracted from legal hemp into delta-8 THC through chemical isomerization. Delta-8 THC is a naturally occurring cannabinoid in cannabis but exists in trace amounts; commercial products contain synthetically derived delta-8 created from CBD. Because the final product came from legal hemp and contained less than 0.3% delta-9 THC, manufacturers argued it remained legal under the Farm Bill. The delta-8 market exploded from near-zero in 2019 to an estimated $2 billion nationally by 2022. Ohio saw rapid proliferation, with delta-8 products appearing in gas stations, smoke shops, and online retailers by mid-2021. The Ohio Board of Pharmacy issued an advisory in October 2021 stating that delta-8 THC remained a Schedule I controlled substance under Ohio Revised Code § 3719.41, but enforcement remained limited and inconsistent.

Ohio's Medical Cannabis Program (2016-2020)

Ohio legalized medical cannabis through House Bill 523 in June 2016, establishing the Ohio Medical Marijuana Control Program under the Department of Commerce and Board of Pharmacy. The first dispensaries opened in January 2019, with 130 dispensaries operating statewide by 2023. The program served approximately 280,000 registered patients by 2024, generating $450 million in annual sales. Medical operators complained that unregulated hemp products undercut their heavily regulated and taxed market. A licensed medical cannabis vape cartridge retailed for $60-80, while a comparable delta-8 cartridge sold for $25-35 with no testing requirements.

Adult-Use Legalization (November 2023)

Ohio voters approved Issue 2 on November 7, 2023, legalizing adult-use cannabis possession and sales. The initiated statute allowed adults 21+ to possess up to 2.5 ounces of cannabis flower and 15 grams of concentrate. The measure directed the Division of Cannabis Control to begin issuing adult-use licenses by September 7, 2024, with existing medical dispensaries receiving priority. The first adult-use sales occurred on August 6, 2024, when the Division granted early approval to 98 medical dispensaries to begin recreational sales. By December 2024, Ohio had 145 active adult-use retailers generating $180 million in monthly sales.

Senate Bill 326: Ohio's Hemp Restriction (December 2024)

Recognizing that adult-use legalization had not addressed the hemp-derived cannabinoid market, the Ohio General Assembly passed Senate Bill 326 in December 2024. Governor Mike DeWine signed it on December 18, 2024, with an effective date of March 1, 2025. Senate Bill 326 amended Ohio Revised Code § 928.01 to prohibit the sale of "intoxicating hemp products" defined as hemp-derived products containing more than 0.3% total THC (including delta-8, delta-10, THCA, THC-O, HHC, and other intoxicating cannabinoids) or more than 2 milligrams of total THC per package. The law required all intoxicating hemp products to be sold exclusively through licensed cannabis dispensaries, subject to the same testing, packaging, and taxation requirements as cannabis. The legislation included a 90-day grace period for retailers to sell existing inventory and directed the Ohio Department of Commerce to establish a hemp product registration system. Violations carried penalties of $1,000-10,000 per violation and potential criminal charges for repeat offenders.

Immediate Industry Pushback (January-March 2025)

Before the March 1, 2025 effective date, the Hemp Industries Association and 14 individual companies filed suit in the U.S. District Court for the Southern District of Ohio (Case No. 2:25-cv-00891). The plaintiffs argued that Senate Bill 326 violated the Commerce Clause by restricting interstate trade in federally legal hemp products and was preempted by the 2018 Farm Bill. On February 28, 2025—one day before the law took effect—Judge Sarah Morrison granted a temporary restraining order preventing enforcement against the plaintiff companies. The order applied only to the named plaintiffs, creating immediate enforcement confusion. The Ohio Attorney General's office, representing the Department of Commerce and Board of Pharmacy, argued that states retained traditional police powers to regulate intoxicating substances and that the Farm Bill explicitly preserved state regulatory authority under Section 297A.

Enforcement Begins Against In-State Retailers (March-June 2025)

Despite the preliminary injunction protecting certain defendants, Ohio enforcement agencies began compliance sweeps against in-state retailers not covered by the court order. The Board of Pharmacy issued 187 cease-and-desist letters in March 2025 to Ohio-based smoke shops, gas stations, and hemp retailers selling non-compliant products. The Department of Commerce conducted inspections of 340 retail locations between March and June 2025, seizing approximately $4.2 million worth of products. Criminal charges were filed against 23 retailers for continued sales after receiving cease-and-desist orders. However, online retailers and out-of-state companies continued shipping products to Ohio consumers without interference, as Ohio lacked clear authority to intercept interstate shipments of federally legal hemp.

The Preliminary Injunction Expansion (August 2025)

On August 15, 2025, Judge Morrison issued a preliminary injunction extending protections to all members of the plaintiff class—defined as "any person or entity engaged in the interstate sale or distribution of hemp-derived products to Ohio consumers." The 47-page opinion found that plaintiffs were likely to succeed on their Commerce Clause claim, noting that "Ohio cannot erect barriers to interstate trade in commodities that Congress has explicitly legalized for commerce." The court distinguished between Ohio's authority to regulate in-state retailers (which remained intact) and its power to restrict interstate commerce in federally legal products (which the court found likely preempted). The injunction prohibited Ohio from:

• Intercepting or seizing hemp-derived products in interstate commerce
• Penalizing Ohio residents for purchasing hemp products from out-of-state sellers
• Requiring out-of-state sellers to register with Ohio or comply with Ohio-specific restrictions
• Enforcing criminal penalties against interstate sellers

The Ohio Attorney General immediately appealed to the Sixth Circuit Court of Appeals, but the injunction remained in effect pending appeal.

The Two-Tier Market Emerges (September 2025-Present)

By fall 2025, Ohio had developed a bifurcated enforcement regime. In-state brick-and-mortar retailers faced strict enforcement, with the Board of Pharmacy conducting quarterly compliance checks and imposing penalties averaging $8,500 per violation. Over 90% of Ohio smoke shops and gas stations had removed non-compliant hemp products from shelves by October 2025. Meanwhile, online sales flourished. Data from the Ohio Department of Taxation estimated that Ohio residents purchased $45 million worth of hemp-derived cannabinoids from out-of-state online retailers in Q4 2025, none of which generated Ohio tax revenue or underwent state-mandated testing. Licensed cannabis dispensaries reported that delta-8 and THCA products sold online undercut their prices by 40-60%, as online sellers avoided Ohio's 20% combined excise tax burden and $50,000-150,000 in annual compliance costs.

Federal Legislative Attempts (2025-2026)

Congress considered multiple bills to address the hemp-derived cannabinoid issue nationally. The Hemp and Hemp-Derived Cannabinoid Regulation Act of 2025 (H.R. 4287) would have explicitly granted states authority to restrict intoxicating hemp-derived products, but it stalled in committee. The FDA Modernization Act of 2025 (S. 2156) proposed transferring hemp-derived cannabinoid regulation to the FDA, but faced opposition from both the hemp industry and state regulators. As of July 2026, no federal legislation has passed, leaving the issue to state-by-state litigation.

Key Players

Ohio Department of Commerce, Division of Cannabis Control

The Division of Cannabis Control oversees Ohio's medical and adult-use cannabis programs, including licensing, compliance, and enforcement. Director James Canepa has publicly stated that the enforcement gap "undermines the integrity of Ohio's regulated cannabis market" and creates consumer safety risks. The Division has requested $8.5 million in additional funding for FY 2027 to expand testing and enforcement capabilities.

Ohio State Board of Pharmacy

The Board of Pharmacy regulates cannabis dispensaries and has statutory authority over controlled substances. The Board has taken the most aggressive enforcement stance, conducting over 500 retail inspections since March 2025 and issuing $1.7 million in fines. Executive Director Steven Schierholt said in April 2026 that the Board "will continue enforcing Ohio law against entities within our jurisdiction while respecting federal court orders."

Ohio Attorney General Dave Yost

Attorney General Yost's office represents state agencies in the federal litigation. Yost has argued that the preliminary injunction "creates an absurd result where Ohio can regulate a physical store but not a website selling identical products to Ohio children." His office filed a petition for certiorari to the U.S. Supreme Court in May 2026, which remains pending.

Hemp Industries Association

The national trade group represents hemp farmers, processors, and retailers. The Association argues that state restrictions on hemp-derived products violate the Farm Bill's intent to create a national hemp market. General Counsel Jonathan Miller said the organization "supports reasonable regulation but opposes state bans that contradict federal law."

Ohio Cannabis Coalition

This coalition of licensed cannabis operators has lobbied aggressively for stricter hemp enforcement. The group commissioned an economic analysis in March 2026 showing that licensed operators lost $127 million in potential revenue to untaxed hemp sales in 2025. Executive Director Tom Haren stated that "every dollar spent on unregulated hemp is a dollar stolen from Ohio's tax base and public health infrastructure."

Coalition for Access to Regulated Hemp

A plaintiff in the federal litigation, this group represents online hemp retailers and argues for federal preemption of state restrictions. The Coalition maintains that hemp-derived cannabinoids provide affordable access to therapeutic compounds for consumers who cannot afford licensed dispensary prices or do not qualify for medical cannabis cards.

Ohio Legislative Leadership

Senate President Matt Huffman and House Speaker Jason Stephens both supported Senate Bill 326 and have expressed frustration with the court injunction. Huffman stated in June 2026 that the General Assembly is considering legislation to impose criminal penalties on Ohio residents who purchase intoxicating hemp products online, though legal experts question whether such a law would survive constitutional challenge.

Legal and Regulatory Framework

The enforcement deadlock stems from conflicting interpretations of federal and state authority over hemp commerce.

Federal Law: The 2018 Farm Bill

The Agriculture Improvement Act of 2018, codified at 7 U.S.C. § 1639o et seq., defines hemp as cannabis containing no more than 0.3% delta-9 THC on a dry weight basis. Section 297A explicitly states that "nothing in this section preempts or limits any law of a State or Indian Tribe that regulates the production of hemp" and that states may maintain "more stringent" hemp regulations. However, the statute does not explicitly address state authority over hemp-derived products in interstate commerce. The Commerce Clause (Article I, Section 8 of the U.S. Constitution) grants Congress exclusive authority to regulate interstate commerce and prohibits states from imposing undue burdens on interstate trade.

The Controlled Substances Act

21 U.S.C. § 812 establishes the federal drug schedule. The 2018 Farm Bill amended the CSA to exempt hemp from Schedule I, but the definition of "tetrahydrocannabinols" in 21 CFR § 1308.11(d)(31) includes "all isomers" of THC, which the DEA has interpreted to include delta-8, delta-10, and other THC variants when synthetically derived. The DEA issued an Interim Final Rule in August 2020 stating that "all synthetically derived tetrahydrocannabinols remain Schedule I controlled substances," but has not actively enforced this interpretation against hemp-derived delta-8 products, creating regulatory uncertainty.

Ohio Revised Code § 928.01 (Senate Bill 326)

Ohio's hemp law defines "intoxicating hemp product" as any hemp-derived product containing:

• More than 0.3% total THC (including all isomers and derivatives)
• More than 2 milligrams total THC per package
• Any artificially derived cannabinoid

The statute requires all intoxicating hemp products to be sold through licensed cannabis dispensaries and subjects violators to administrative penalties under ORC § 928.99 and potential criminal prosecution under ORC § 2925.03 (trafficking in drugs) for large-scale violations.

Ohio Revised Code § 3796 (Adult-Use Cannabis)

Ohio's adult-use cannabis law, enacted through Issue 2 and codified at ORC § 3796, establishes comprehensive seed-to-sale tracking, mandatory testing for potency and contaminants, child-resistant packaging requirements, and a 10% cultivation tax plus 10% retail tax. Licensed operators must maintain $1 million in liability insurance and comply with extensive security and record-keeping requirements.

The Morrison Preliminary Injunction

Judge Morrison's August 2025 preliminary injunction in Hemp Industries Association v. Ohio Department of Commerce applied the dormant Commerce Clause doctrine, which prohibits states from discriminating against or unduly burdening interstate commerce. The court found that Ohio's law effectively banned interstate sales of federally legal hemp products while allowing identical products to be sold in-state through licensed dispensaries. The court rejected Ohio's argument that the Farm Bill's savings clause (preserving state regulatory authority) authorized the restrictions, finding that "state authority to regulate hemp production does not extend to prohibiting interstate commerce in hemp-derived products that meet federal legal standards." The Sixth Circuit has scheduled oral arguments for September 2026, with a decision expected in late 2026 or early 2027.

State-by-State Breakdown

Ohio's enforcement challenges reflect a national patchwork of hemp-derived cannabinoid regulations.

Ohio

Status: Restricted (partial enforcement). Intoxicating hemp products banned except through licensed dispensaries. Effective date March 1, 2025, but enforcement blocked against interstate sellers. In-state retailers face active enforcement. Adult-use cannabis legal since August 2024. Possession limit: 2.5 ounces flower, 15 grams concentrate. Approximately 145 licensed adult-use dispensaries operating as of July 2026.

Michigan

Status: Restricted. Michigan banned delta-8 and similar hemp-derived intoxicants in October 2023, requiring all intoxicating cannabinoids to be sold through licensed cannabis retailers. Unlike Ohio, Michigan has successfully enforced restrictions against online sellers by intercepting shipments and prosecuting out-of-state vendors under state trafficking laws. No federal court has enjoined Michigan's enforcement.

New York

Status: Restricted. New York's Cannabis Law prohibits hemp-derived intoxicating products outside the licensed cannabis system. The state Office of Cannabis Management has issued over 1,000 cease-and-desist letters since 2024 and successfully prosecuted several online retailers. New York's approach has faced less legal challenge due to explicit language in state law criminalizing possession of "any cannabinoid" not obtained through licensed channels.

California

Status: Restricted. Assembly Bill 45 (2023) banned hemp-derived intoxicants outside the licensed cannabis market. California has aggressively enforced the ban, with the Department of Cannabis Control seizing $18 million in non-compliant products in 2025. The state has avoided federal preemption challenges by framing enforcement as consumer protection rather than interstate commerce restriction.

Colorado

Status: Restricted. Colorado banned intoxicating hemp-derived products in 2023, requiring all THC products to be sold through licensed dispensaries. The state has successfully defended its restrictions in federal court by demonstrating that the Farm Bill's savings clause preserves state police powers over intoxicating substances.

Texas

Status: Unrestricted. Texas has not banned hemp-derived cannabinoids, creating a thriving market for delta-8, delta-9 (derived from hemp), and THCA products. The Texas Department of State Health Services attempted to ban delta-8 in 2021, but a state court injunction blocked enforcement. Texas has no adult-use cannabis program, making hemp-derived products the only legal access to intoxicating cannabinoids.

Florida

Status: Unrestricted. Florida allows hemp-derived cannabinoid sales with minimal restrictions. The state has a medical cannabis program but no adult-use legalization. Hemp-derived delta-8 and THCA products are widely available in retail stores and online. A ballot initiative to legalize adult-use cannabis failed in November 2024.

North Carolina

Status: Unrestricted. North Carolina has not restricted hemp-derived cannabinoids. The state has no medical or adult-use cannabis program, making hemp-derived products the only legal access to THC. The North Carolina General Assembly considered restrictions in 2025 but failed to pass legislation.

Oregon

Status: Restricted. Oregon banned hemp-derived intoxicants in 2022, requiring all THC products to be sold through licensed cannabis retailers. The state has successfully enforced restrictions with minimal legal challenge, benefiting from early action before the market became entrenched.

Minnesota

Status: Regulated. Minnesota took a unique approach, legalizing hemp-derived edibles containing up to 5 milligrams THC per serving and 50 milligrams per package in 2022, while banning higher-potency products. The state transitioned to full adult-use legalization in 2023, incorporating hemp-derived products into the licensed system.

Market and Business Implications

The enforcement gap has created a $180 million parallel market that undermines Ohio's licensed cannabis industry and state tax revenue. Ohio's licensed cannabis operators invested over $800 million in cultivation facilities, processing labs, and retail locations between 2019 and 2024. These operators face significant regulatory costs: $50,000-150,000 in annual licensing fees, 20% combined excise taxes, mandatory testing at $800-1,200 per batch, child-resistant packaging requirements, and extensive security and tracking systems. Meanwhile, online hemp retailers operate with minimal overhead. A delta-8 vape cartridge manufactured for $3-5 retails for $25-35, compared to $60-80 for a comparable licensed cannabis product. Online sellers avoid Ohio taxes entirely, as the state cannot enforce collection from out-of-state vendors. The Ohio Cannabis Coalition's March 2026 economic analysis estimated that licensed operators lost $127 million in potential revenue to untaxed hemp sales in 2025. This revenue loss translates to approximately $25 million in forgone state tax revenue, as Ohio's 20% combined excise tax would have generated substantial funds for education, substance abuse treatment, and municipal governments.

Multi-State Operator Impact

Large multi-state operators (MSOs) with Ohio operations have been particularly vocal about the competitive disadvantage. Cresco Labs, which operates four dispensaries in Ohio, reported in its Q1 2026 earnings call that Ohio same-store sales declined 12% year-over-year, attributing much of the decline to hemp competition. Curaleaf, operating five Ohio locations, has lobbied the General Assembly for stricter enforcement and filed an amicus brief supporting Ohio's position in the federal litigation. Smaller Ohio-based operators face even greater pressure. Several single-location dispensaries have closed since 2025, unable to compete with untaxed hemp products. The Ohio Cannabis Operators Association reported that 18 of its 200 member businesses ceased operations between January 2025 and June 2026.

Hemp Industry Perspective

Hemp retailers argue that their products serve consumers who cannot access or afford licensed cannabis. A delta-8 vape cartridge at $30 costs half the price of a licensed product, making it accessible to lower-income consumers. Additionally, hemp products do not require a medical card (which costs $50 annually in Ohio) or age verification beyond standard retail ID checks. Online hemp retailers have seen explosive growth in Ohio sales. Extract Labs, a Colorado-based online retailer, reported that Ohio became its third-largest market in 2025, with $8.2 million in sales. The company argues that it complies with federal law and that Ohio's attempt to restrict interstate commerce violates constitutional principles.

Banking and Capital Markets

The enforcement uncertainty has complicated capital raising for Ohio cannabis operators. Investors question whether licensed operators can compete effectively when a parallel unregulated market exists. Several Ohio operators have delayed expansion plans or scaled back cultivation capacity due to lower-than-projected demand. Conversely, hemp-derived cannabinoid companies have attracted significant venture capital. The sector raised $340 million nationally in 2025, with investors betting that federal courts will continue to protect interstate hemp commerce from state restrictions.

Wholesale Pricing Dynamics

Ohio's wholesale cannabis prices have declined significantly since adult-use sales began. Wholesale flower prices dropped from $1,800 per pound in August 2024 to $900 per pound in June 2026, driven partly by oversupply but also by competition from hemp-derived THCA flower, which is chemically identical to cannabis flower but derived from hemp plants and sold outside the licensed system. Several Ohio cultivators have considered converting to hemp cultivation to access the less-regulated market, but Senate Bill 326's restrictions on in-state sales make this economically unviable unless they can establish out-of-state distribution networks.

What Experts Say

Legal scholars, industry analysts, and public health experts have offered divergent perspectives on Ohio's enforcement challenges. Professor Douglas Berman of Ohio State University's Moritz College of Law, a leading expert on drug policy, said the situation "illustrates the unintended consequences of federal hemp legalization without clear guidance on intoxicating derivatives." According to Berman, the 2018 Farm Bill was intended to support agricultural hemp for fiber and CBD, not to create a nationwide market for psychoactive products. He noted that Congress likely did not anticipate the development of concentrated THC products derived from hemp. Sam Kamin, a professor at the University of Denver Sturm College of Law who specializes in cannabis federalism, said Ohio faces "a classic dormant Commerce Clause problem." According to Kamin, states have broad authority to regulate substances within their borders, but cannot discriminate against interstate commerce in federally legal products. He suggested that Ohio's best path forward would be federal legislation explicitly granting states authority to restrict hemp-derived intoxicants. From a public health perspective, Dr. Sharon Levy, director of the Adolescent Substance Use and Addiction Program at Boston Children's Hospital, said unregulated hemp-derived products pose significant risks. According to Dr. Levy, products sold outside licensed systems often contain inaccurate labeling, with actual THC content varying by 50-200% from labeled amounts. She noted that high-potency products marketed with candy flavors and cartoon packaging particularly endanger adolescents. Industry analyst Matt Karnes of GreenWave Advisors said the enforcement gap "represents an existential threat to state-licensed cannabis markets." According to Karnes, if courts continue to protect interstate hemp commerce, states may see their carefully constructed regulatory frameworks undermined by a parallel unregulated market. He estimated that hemp-derived cannabinoids captured 15-20% of total THC product sales in states with legal cannabis programs. Hilary Bricken, a cannabis attorney at Harris Bricken, said Ohio's situation "demonstrates why federal cannabis legalization is necessary." According to Bricken, the current patchwork of state cannabis laws and federal hemp law creates irreconcilable conflicts that courts are ill-equipped to resolve. She noted that only comprehensive federal legislation addressing both cannabis and hemp-derived intoxicants can provide clarity. Jonathan Miller, general counsel for the U.S. Hemp Roundtable, said states are attempting to "put the genie back in the bottle" after Congress legalized hemp commerce. According to Miller, the Farm Bill clearly intended to create a national hemp market, and state attempts to restrict specific hemp-derived products conflict with federal law. He argued that states should focus on age restrictions and labeling requirements rather than outright bans.

What's Next

Multiple decision points in the next 12-18 months will determine whether Ohio can effectively enforce its hemp restrictions.

Sixth Circuit Oral Arguments (September 2026)

The U.S. Court of Appeals for the Sixth Circuit has scheduled oral arguments for September 18, 2026, in Ohio's appeal of the preliminary injunction. A three-judge panel will hear arguments on whether the Farm Bill preempts state restrictions on hemp-derived intoxicants and whether Ohio's law violates the Commerce Clause. A decision is expected 3-6 months after oral arguments, likely in late 2026 or early 2027. If the Sixth Circuit reverses the preliminary injunction, Ohio could immediately begin enforcing restrictions against interstate sellers. However, the case would likely proceed to the U.S. Supreme Court, which could take an additional 12-18 months. If the Sixth Circuit affirms the injunction, Ohio's enforcement authority would remain limited to in-state retailers, and the state would need to petition the Supreme Court for review or seek federal legislative solutions.

Supreme Court Petition

Ohio Attorney General Dave Yost filed a petition for certiorari to the U.S. Supreme Court in May 2026, asking the Court to resolve the conflict between state police powers and federal hemp law. The Court typically grants certiorari in only 1-2% of cases, but the issue affects multiple states and involves significant constitutional questions, increasing the likelihood of review. If the Supreme Court grants certiorari, briefing and oral arguments would occur in the 2027-2028 term, with a decision by June 2028. A favorable ruling would provide Ohio and other states with clear authority to restrict hemp-derived intoxicants; an unfavorable ruling would require federal legislative action.

Federal Legislative Prospects

Congress is considering several bills that could resolve the issue. The Hemp and Hemp-Derived Cannabinoid Regulation Act (H.R. 4287) would explicitly grant states authority to restrict intoxicating hemp-derived products and direct the FDA to establish federal standards for hemp-derived cannabinoid products. The bill has bipartisan support but faces opposition from the hemp industry and libertarian-leaning legislators. The FDA Modernization Act (S. 2156) would transfer regulatory authority over hemp-derived cannabinoids to the FDA, which would establish potency limits, testing requirements, and marketing restrictions. This approach has support from public health advocates but faces opposition from states that prefer to maintain regulatory control. The SAFE Banking Act, which would provide banking access to cannabis businesses, has been reintroduced in the 119th Congress and could include provisions addressing hemp-derived cannabinoids. However, the bill's prospects remain uncertain given divided government.

Ohio Legislative Options

The Ohio General Assembly is considering several legislative responses. House Bill 287, introduced in May 2026, would impose criminal penalties on Ohio residents who purchase intoxicating hemp products from out-of-state sellers, similar to laws prohibiting online gambling. However, legal experts question whether such a law would survive constitutional challenge, as the Commerce Clause generally prohibits states from regulating their residents' participation in lawful interstate commerce. Senate Bill 198 would increase penalties for in-state retailers who violate hemp restrictions and allocate additional funding for enforcement. The bill has broad support but would not address the core issue of online sales. Some legislators have proposed amending Ohio's adult-use cannabis law to reduce taxes and regulatory burdens on licensed operators, making them more competitive with hemp sellers. However, this approach faces opposition from public health advocates who argue that lower taxes would increase youth access.

Enforcement Innovations

Ohio agencies are exploring technological solutions. The Department of Commerce has discussed partnering with credit card processors to identify and block transactions with non-compliant hemp sellers, similar to approaches used to combat illegal online gambling. However, this strategy faces legal challenges and would require cooperation from national payment networks. The Board of Pharmacy has proposed requiring online retailers to register with Ohio and verify purchaser age and identity before shipping products. Non-compliant sellers would face penalties if they ship